Recent advances on Hepatitis C virus in dialysis population

Fabrizio Fabrizi, Piergiorgio Messa, Paul Martin

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) infection remains common among patients undergoing regular dialysis and good evidence supports the detrimental role of HCV on survival in patients undergoing maintenance dialysis. According to an updated meta-analysis of clinical studies (n=15; 195,370 unique patients on maintenance dialysis), the summary estimate for adjusted relative risk (allcause mortality) with anti-HCV across the published studies was 1.32 with a 95% Confidence Intervals of 1.24; 1.42, homogeneity assumption was not rejected. Various mechanisms support the excess death risk of HCV-infected patients on regular dialysis, in addition to liver disease-related mortality. The adjusted relative risk for cardiovascular mortality among HCV-infected patients on regular dialysis was 1.26 (95% Confidence Intervals, 1.10; 1.45); the increased cardiovascular mortality in anti-HCV positive patients has been associated in part to malnutrition and chronic inflammation. The current standard of care for HCV in dialysis population is combined antiviral therapy (pegylated interferon plus ribavirin) with a rate of viral response of around 60%. Triple therapy with telaprevir proved to be effective and safe in dialysis patients with HCV but only anecdotal evidence exists. Antiviral treatment of HCV-infected patients on maintenance dialysis could lead to cure the liver damage and the extrahepatic complications. The future availability of all-oral interferon/ribavirin free regimens for antiviral treatment of HCV will help nephrologists to improve survival in this high-risk group.

Original languageEnglish
Pages (from-to)260-271
Number of pages12
JournalKidney and Blood Pressure Research
Volume39
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Hepacivirus
Dialysis
Population
Antiviral Agents
Mortality
Ribavirin
Maintenance
Interferons
Confidence Intervals
Survival
Virus Diseases
Therapeutics
Standard of Care
Malnutrition
Meta-Analysis
Liver Diseases
Inflammation
Liver

Keywords

  • Cardiovascular diseases
  • Dialysis
  • Hepatitis C Virus
  • Inflammation
  • Nutrition

ASJC Scopus subject areas

  • Nephrology
  • Cardiology and Cardiovascular Medicine

Cite this

Recent advances on Hepatitis C virus in dialysis population. / Fabrizi, Fabrizio; Messa, Piergiorgio; Martin, Paul.

In: Kidney and Blood Pressure Research, Vol. 39, No. 4, 01.01.2014, p. 260-271.

Research output: Contribution to journalArticle

Fabrizi, Fabrizio ; Messa, Piergiorgio ; Martin, Paul. / Recent advances on Hepatitis C virus in dialysis population. In: Kidney and Blood Pressure Research. 2014 ; Vol. 39, No. 4. pp. 260-271.
@article{2acf9e344d0c4dc59605e7d96310efb4,
title = "Recent advances on Hepatitis C virus in dialysis population",
abstract = "Hepatitis C virus (HCV) infection remains common among patients undergoing regular dialysis and good evidence supports the detrimental role of HCV on survival in patients undergoing maintenance dialysis. According to an updated meta-analysis of clinical studies (n=15; 195,370 unique patients on maintenance dialysis), the summary estimate for adjusted relative risk (allcause mortality) with anti-HCV across the published studies was 1.32 with a 95{\%} Confidence Intervals of 1.24; 1.42, homogeneity assumption was not rejected. Various mechanisms support the excess death risk of HCV-infected patients on regular dialysis, in addition to liver disease-related mortality. The adjusted relative risk for cardiovascular mortality among HCV-infected patients on regular dialysis was 1.26 (95{\%} Confidence Intervals, 1.10; 1.45); the increased cardiovascular mortality in anti-HCV positive patients has been associated in part to malnutrition and chronic inflammation. The current standard of care for HCV in dialysis population is combined antiviral therapy (pegylated interferon plus ribavirin) with a rate of viral response of around 60{\%}. Triple therapy with telaprevir proved to be effective and safe in dialysis patients with HCV but only anecdotal evidence exists. Antiviral treatment of HCV-infected patients on maintenance dialysis could lead to cure the liver damage and the extrahepatic complications. The future availability of all-oral interferon/ribavirin free regimens for antiviral treatment of HCV will help nephrologists to improve survival in this high-risk group.",
keywords = "Cardiovascular diseases, Dialysis, Hepatitis C Virus, Inflammation, Nutrition",
author = "Fabrizio Fabrizi and Piergiorgio Messa and Paul Martin",
year = "2014",
month = "1",
day = "1",
doi = "10.1159/000355803",
language = "English",
volume = "39",
pages = "260--271",
journal = "Kidney and Blood Pressure Research",
issn = "1420-4096",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Recent advances on Hepatitis C virus in dialysis population

AU - Fabrizi, Fabrizio

AU - Messa, Piergiorgio

AU - Martin, Paul

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Hepatitis C virus (HCV) infection remains common among patients undergoing regular dialysis and good evidence supports the detrimental role of HCV on survival in patients undergoing maintenance dialysis. According to an updated meta-analysis of clinical studies (n=15; 195,370 unique patients on maintenance dialysis), the summary estimate for adjusted relative risk (allcause mortality) with anti-HCV across the published studies was 1.32 with a 95% Confidence Intervals of 1.24; 1.42, homogeneity assumption was not rejected. Various mechanisms support the excess death risk of HCV-infected patients on regular dialysis, in addition to liver disease-related mortality. The adjusted relative risk for cardiovascular mortality among HCV-infected patients on regular dialysis was 1.26 (95% Confidence Intervals, 1.10; 1.45); the increased cardiovascular mortality in anti-HCV positive patients has been associated in part to malnutrition and chronic inflammation. The current standard of care for HCV in dialysis population is combined antiviral therapy (pegylated interferon plus ribavirin) with a rate of viral response of around 60%. Triple therapy with telaprevir proved to be effective and safe in dialysis patients with HCV but only anecdotal evidence exists. Antiviral treatment of HCV-infected patients on maintenance dialysis could lead to cure the liver damage and the extrahepatic complications. The future availability of all-oral interferon/ribavirin free regimens for antiviral treatment of HCV will help nephrologists to improve survival in this high-risk group.

AB - Hepatitis C virus (HCV) infection remains common among patients undergoing regular dialysis and good evidence supports the detrimental role of HCV on survival in patients undergoing maintenance dialysis. According to an updated meta-analysis of clinical studies (n=15; 195,370 unique patients on maintenance dialysis), the summary estimate for adjusted relative risk (allcause mortality) with anti-HCV across the published studies was 1.32 with a 95% Confidence Intervals of 1.24; 1.42, homogeneity assumption was not rejected. Various mechanisms support the excess death risk of HCV-infected patients on regular dialysis, in addition to liver disease-related mortality. The adjusted relative risk for cardiovascular mortality among HCV-infected patients on regular dialysis was 1.26 (95% Confidence Intervals, 1.10; 1.45); the increased cardiovascular mortality in anti-HCV positive patients has been associated in part to malnutrition and chronic inflammation. The current standard of care for HCV in dialysis population is combined antiviral therapy (pegylated interferon plus ribavirin) with a rate of viral response of around 60%. Triple therapy with telaprevir proved to be effective and safe in dialysis patients with HCV but only anecdotal evidence exists. Antiviral treatment of HCV-infected patients on maintenance dialysis could lead to cure the liver damage and the extrahepatic complications. The future availability of all-oral interferon/ribavirin free regimens for antiviral treatment of HCV will help nephrologists to improve survival in this high-risk group.

KW - Cardiovascular diseases

KW - Dialysis

KW - Hepatitis C Virus

KW - Inflammation

KW - Nutrition

UR - http://www.scopus.com/inward/record.url?scp=84906614459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906614459&partnerID=8YFLogxK

U2 - 10.1159/000355803

DO - 10.1159/000355803

M3 - Article

VL - 39

SP - 260

EP - 271

JO - Kidney and Blood Pressure Research

JF - Kidney and Blood Pressure Research

SN - 1420-4096

IS - 4

ER -